Grufity logo
Grufity logo
PTGX

PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

$155.14+3.72 (+2.46%)
Market Closed as of 14 Aug 2026, 04:00 pm ET

PTGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTGX Price Action

Last 7 days

6.4%

Last 30 days

14.5%

Last 90 days

51.8%

Trailing 12 Months

182.1%

PTGX RSI Chart

PTGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTGX Valuation

Market Cap

10.0B

Price/Earnings (Trailing)

121.08

Price/Sales (Trailing)

135.54

EV/EBITDA

112

Price/Free Cashflow

76.88

PTGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

74.1M

Rev. Growth (Yr)

-95.64%

Rev. Growth (Qtr)

57.83%

PTGX Earnings

Earnings (TTM)

82.9M

Earnings Growth (Yr)

568.35%

Earnings Growth (Qtr)

4.2K%

PTGX Profitability

EBT Margin

113.87%

Return on Equity

9.85%

Return on Assets

9.36%

Free Cashflow Yield

1.3%

PTGX Investor Care

Shares Dilution (1Y)

4.19%

Diluted EPS (TTM)

1.02

PTGX Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)
Revenue & Growth

How Protagonist Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202674.1M---
2025207.8M209.2M209.2M46.0M
2024153.6M247.2M340.8M434.4M
2023---60.0M
202246.9M45.5M36.0M26.6M
202129.5M30.2M27.4M27.4M
2020--23.1M25.7M
201921.7M---
201831.3M42.5M39.9M30.9M
2017---20.1M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Protagonist Therapeutics Inc

PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
 CEO
 WEBSITEprotagonist-inc.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES106

Protagonist Therapeutics Inc Frequently Asked Questions

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Aug 14 2026, market cap of Protagonist Therapeutics Inc is 10.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Aug 14 2026, PTGX's PE ratio (Price to Earnings) is 121.08 and Price to Sales (PS) ratio is 135.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Protagonist Therapeutics Inc has provided 0.298 (multiply by 100 for percentage) rate of return.